Novel Radiopharmaceuticals for Tumor
Preparation of 68Ga labeled pre-targeted molecular probe based on bio-orthogonal Diels-Alder click chemistry and CD11b receptor targeted imaging in CT26 colon cancer mouse models
Zhang Yinging, Shi Dai, Xu Zhan, Cheng Yuan, Cheng Dengfeng
Published 2021-10-25
Cite as Chin J Nucl Med Mol Imaging, 2021, 41(10): 585-591. DOI: 10.3760/cma.j.cn321828-20210701-00218
Abstract
ObjectiveTo prepare a 68Ga labeled probe targeting integrin alpha M(CD11b) receptor, namely 68Ga-1, 4, 7-triazacyclononane-1, 4, 7-triacetic acid-Glycine-Arginine-Glutamate-Arginine-Glutamate-polyethylene glycol11-1, 2, 4, 5-terazine/CD11b antibody-F(ab′)2-trans-cyclooctene (68Ga-NOTA-Polypeptide-PEG11-Tz/anti-CD11b-F(ab′)2-TCO), and to explore its feasibility as a molecular probe for CD11b receptor through microPET imaging.
MethodsImmunofluorescence was used to detect the expression of CD11b on the surface of RAW264.7 cell. CD11b specific monoclonal antibody (M1/70) was conjugated with TCO, and anti-CD11b-F(ab′)2-TCO fragment was obtained. The ligand NOTA-Polypeptide-PEG11-Tz was labeled with 68Ga, and its specific activity and radiochemical purity were detected. Pre-targeted cell binding experiment was conducted to evaluate the binding ability of molecular probe. CT26 colon cancer bearing mouse models were established, and then pre-targeted biodistribution and imaging experiments were performed. Immunohistochemical experiment was used to verify the expression of CD11b receptor in tumor. The one-way analysis of variance was used to compare the data.
ResultsThe results of immunofluorescence demonstrated CD11b receptor was highly expressed on the surface of RAW264.7 cell. Anti-CD11b-F(ab′)2-TCO fragment was verified by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 68Ga-NOTA-Polypeptide-PEG11-Tz was successfully synthesized, with the labeling efficiency of 94.6%. The specific activity was 7.0-7.4 MBq/μg, and the radiochemical purity was higher than 95%. Pre-targeted cell binding experiment confirmed that the molecular probe bound to the CD11b receptor. The biodistribution and imaging experiments showed that the kidney radioactivity uptake was high at pre-targeted 4, 12 and 24 h intervals, which proved that probe was excreted through the urinary system. In addition, molecular probe had higher radioactive uptake at the tumor site, with the tumor/muscle ratios of 9.23±1.45, 12.53±1.36 and 10.74±1.11 (F=848.8, P<0.05). When the radioligand was injected 1 h after the pre-positioned 12 h interval, the images contrast was the best, with the standardized uptake value (SUV) in tumor and muscle of 0.67±0.12, 0.09±0.04, respectively. Immunohistochemistry verified the highly expression of CD11b receptor in tumor.
ConclusionsThe pre-targeted molecular probe 68Ga-NOTA-Polypeptide-PEG11-Tz/anti-CD11b-F(ab′)2-TCO is successfully synthesized. The molecular probe has targeting ability for CD11b+ colon cancer, and is expected to be used as a tracer targeting CD11b receptor in vivo.
Key words:
Antigens, CD11b; Isotope labeling; Gallium radioisotopes; Click chemistry; Positron-emission tomography; Colonic neoplasms; Mice
Contributor Information
Zhang Yinging
Shanghai Institute of Medical Imaging
Department of Nuclear Medicine, Zhongshan Hospital, Fudan University
Nuclear Medicine Institute of Fudan University
Cancer Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Shi Dai
Shanghai Institute of Medical Imaging
Department of Nuclear Medicine, Zhongshan Hospital, Fudan University
Nuclear Medicine Institute of Fudan University
Cancer Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Xu Zhan
Shanghai Institute of Medical Imaging
Department of Nuclear Medicine, Zhongshan Hospital, Fudan University
Nuclear Medicine Institute of Fudan University
Cancer Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Cheng Yuan
Shanghai Institute of Medical Imaging
Department of Nuclear Medicine, Zhongshan Hospital, Fudan University
Nuclear Medicine Institute of Fudan University
Cancer Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Cheng Dengfeng
Shanghai Institute of Medical Imaging
Department of Nuclear Medicine, Zhongshan Hospital, Fudan University
Nuclear Medicine Institute of Fudan University
Cancer Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China